The GLP Chatroom Community Rules — Updated January 2026
Public Square is a small room with a long memory. These are the house rules; they are short because we would rather enforce a few things properly than list twenty and mean none of them.
The rules
- Argue with the claim, never the person. Hard disagreement is the point of this board. Contempt is not, and it is the one thing that gets a post removed without discussion.
- Say where it came from. A clinical claim needs a source, and “I read it somewhere” is an invitation to go and find where. Nobody is asked to cite their own experience — only to label it as experience.
- No purchase links, anywhere. Not in a post, not in a signature, not by private message. Vendor discussion belongs in the review sections; vendor traffic belongs somewhere else.
- Nothing here is medical advice, including anything written by a member who tells you what they do for a living. Take it to somebody who can examine you.
- Declare an interest. If you have any commercial relationship with a supplier, say so in the post. Undisclosed promotion is the only offence here with no second chance.
- Search first. Most questions have been answered at length, usually better than they will be answered again today.
- Correct yourself in public. Editing a mistake away helps nobody; a correction underneath it helps the next person who made the same one.
- No politics, no religion, and no diagnosing strangers.
How this is enforced
First time, a note from a moderator. Second time, a week off. Third time, permanently, and we do not debate it in the thread. Undisclosed promotion and scam posts skip straight to the third step.
Disagree with a decision? Message the moderators. Arguing about moderation inside a thread derails the thread, which is the actual harm.
Admin said:The GLP Chatroom Community Rules — Updated January 2026 Public Square is a small room with a long memory.
Agreed, and subgroup analyses deserve particular suspicion. With enough subgroups something is significant by chance, and pre-registered subgroups are a different animal from ones found afterwards.
Admin said:The GLP Chatroom Community Rules — Updated January 2026 Public Square is a small room with a long memory.
This is where I part company with the consensus forming above. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsThis one has a reasonably settled answer, so here it is. Read four things before the headline number. The population, because trial populations are selected and supported in ways that real cohorts are not. The comparator, because "better than placebo" and "better than the current standard" are different claims and get reported identically. The primary endpoint as pre-registered, because a secondary endpoint promoted after the fact is a hypothesis rather than a finding. And the completion rate, because a large effect in the half of participants who finished is a different result from a large effect in everybody enrolled.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
InsuranceTom said:Agreed, and subgroup analyses deserve particular suspicion.
Can confirm the pattern InsuranceTom describes. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.